Prognostic and predictive biomarkers in resected colon cancer: Current status and future perspectives for integrating genomics into biomarker discovery

Oncologist

Volumn 15, Issue 4, 2010, Pages 390-404

  Tejpar, Sabine ^a   Bertagnolli, Monica ^b   Bosman, Fred ^c   Lenz, Heinz Joseph ^d   Garraway, Levi ^e   Waldman, Frederic ^f   Warren, Robert ^f   Bild, Andrea ^g   Collins Brennan, Denise ^b   Hahn, Hejin ^h   Harkin, D Paul ⁱ   Kennedy, Richard ⁱ   Ilyas, Mohammad ^j   Morreau, Hans ^k   Proutski, Vitali ⁱ   Swanton, Charles ^l   Tomlinson, Ian ^m   Delorenzi, Mauro ⁿ   Fiocca, Roberto ^o   van Cutsem, Eric ^a   Roth, Arnaud ^p   more..

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF UTAH   (United States)

^h VIRGINIA MASON MEDICAL CENTER   (United States)

ⁱ Almac Sciences   (United Kingdom)

^j UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^k LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^l ROYAL MARSDEN HOSPITAL   (United Kingdom)

^m IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

ⁿ SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^o UNIVERSITY OF GENOA   (Italy)

^p GENEVA UNIVERSITY HOSPITALS   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; BEVACIZUMAB; BIOLOGICAL MARKER; FLUOROURACIL; FOLINIC ACID; GUANINE NUCLEOTIDE BINDING PROTEIN; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; THYMIDYLATE SYNTHASE;

ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PATIENT; CANCER RESEARCH; CHROMOSOME 18Q; CLINICAL TRIAL; COLON CANCER; COLON RESECTION; GENOMICS; HUMAN; MICROSATELLITE INSTABILITY; MOLECULAR GENETICS; ONCOGENE K RAS; POSTOPERATIVE CARE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS;

CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; GENES, P53; GENOMIC INSTABILITY; GENOMICS; HUMANS; MICROSATELLITE INSTABILITY; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 77951711694     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0233     Document Type: Article

References (154)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. O'Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst 2004;96:1420-1425.
3. Gill S, Loprinzi CL, Sargent DJ et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: Who benefits and by how much? J Clin Oncol 2004;22:1797-1806.
4. André T, Quinaux E, Louvet C et al. Phase III study comparing a semimonthly with a monthly regimen of fluorouracil and leucovorin as adjuvant treatment for stage II and III colon cancer patients: Final results of GERCOR C96.1. J Clin Oncol 2007;25:3732-3738.
5. Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: Results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999;17:1349-1355.
6. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-3116.
7. Van Cutsem E, Labianca R, Bodoky G et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009;27:3117-3125.
8. Saltz LB, Niedzwiecki D, Hollis D et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: Results of CALGB 89803. J Clin Oncol 2007;25:3456-3461.
9. Le Voyer TE, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: A secondary survey of intergroup trial INT-0089. J Clin Oncol 2003;21:2912-2919.
10. Bosman FT, Yan P, Tejpar S et al. Tissue biomarker development in a multicentre trial context: A feasibility study on the PETACC3 stage II and III colon cancer adjuvant treatment trial. Clin Cancer Res 2009;15:5528-5533.
11. Segditsas S, Tomlinson I. Colorectal cancer and genetic alterations in the Wnt pathway. Oncogene 2006;25:7531-7537.
12. Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988;319:525-532.
13. Vogelstein B, Fearon ER, Kern SE et al. Allelotype of colorectal carcinomas. Science 1989;244:207-211.
14. Baker SJ, Fearon ER, Nigro JM et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science 1989;244:217-221.
15. Markowitz SD, Bertagnolli MM. Molecular origins of cancer: Molecular basis of colorectal cancer. N Engl J Med 2009;361:2449-2460.
16. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998;396:643-649.
17. Lothe RA, Peltomaki P, Meling GI et al. Genomic instability in colorectal cancer: Relationship to clinicopathological variables and family history. Cancer Res 1993;53:5849-5852.
18. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev 2004;23:11-27.
19. Aaltonen LA, Peltomäki P, Leach FS et al. Clues to the pathogenesis of familial colorectal cancer. Science 1993;260:812-816.
20. Ionov Y, Peinado MA, Malkhosyan S et al. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature 1993;363:558-561.
21. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996;87:159-170.
22. Kane MF, Loda M, Gaida GM et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. Cancer Res 1997;57:808-811.
23. Cunningham JM, Christensen ER, Tester DJ et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998;58:3455-3460.
24. Hendriks YM, de Jong AE, Morreau H et al. Diagnostic approach and management of Lynch syndrome (hereditary nonpolyposis colorectal carcinoma): A guide for clinicians. CA Cancer J Clin 2006;56:213-225.
25. Duval A, Hamelin R. Mutations at coding repeat sequences in mismatch repair-deficient human cancers: Toward a new concept of target genes for instability. Cancer Res 2002;62:2447-2454.
26. Miquel C, Jacob S, Grandjouan S et al. Frequent alteration of DNA damage signalling and repair pathways in human colorectal cancers with microsatellite instability. Oncogene 2007;26:5919-5926.
27. Oliveira C, Pinto M, Duval A et al. BRAF mutations characterize colon but not gastric cancer with mismatch repair deficiency. Oncogene 2003;22:9192-9196.
28. Toyota M, Ahuja N, Ohe-Toyota M et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999;96:8681-8686.
29. Shen L, Toyota M, Kondo Y et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007;104:18654-18659.
30. Umar A, Boland CR, Terdiman JP et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004;96:261-268.
31. Koopman M, Kortman GA, Mekenkamp L et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer 2009;100:266-273.
32. Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000;342:69-77.
33. Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003;349:247-257.
34. Halling KC, French AJ, McDonnell SK et al. Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers. J Natl Cancer Inst 1999;91:1295-1303.
35. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005;23:609-618.
36. Roth AD, Tejpar S, Yan P et al. Stage-specific prognostic value of molecular markers in colon cancer: Results of the translational study on the PETACC 3-EORTC 40993-SAKK 60-00 trial [abstract 4002]. J Clin Oncol 2009;27(15 suppl):169s.
37. Kerr D, Gray R, Quirke P et al. A quantitative multigene RT-PCR assay for prediction of recurrence in stage II colon cancer: Selection of the genes in four large studies and results of the independent, prospectively designed QUASAR validation study [abstract 4000]. J Clin Oncol 2009;25(15 suppl):169s.
38. Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001;1:104-109.
39. Sargent DJ, Marsoni S, Thibodeau SN et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): A pooled molecular reanalysis of randomized chemotherapy trials [abstract 4008]. J Clin Oncol 2008;26:180s.
40. Jover R, Zapater P, Castells A et al. The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status. Eur J Cancer 2009;45:365-373.
41. Bertagnolli MM, Niedzwiecki D, Compton CC et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol 2009;27:1814-1821.
42. Tejpar S, Bosman F, Delorenzi M et al. Microsatellite instability (MSI) in stage II and III colon cancer treated with 5FU-LV or 5FU-LV and irinotecan (PETACC 3-EORTC 40993-SAKK 60/00 trial) [abstract 4001]. J Clin Oncol 2009;27(15 suppl):169s.
43. Sinicrope FA, Sargent DJ. Clinical implications of microsatellite instability in sporadic colon cancers. Curr Opin Oncol 2009;21:369-373.
44. French AJ, Sargent DJ, Burgart LJ et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin Cancer Res 2008;14:3408-3415.
45. Jen J, Kim H, Piantadosi S et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer. N Engl J Med 1994;331:213-221.
46. Ogunbiyi OA, Goodfellow PJ, Herfarth K et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998;16:427-433.
47. Popat S, Houlston RS. A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis. Eur J Cancer 2005;41:2060-2070.
48. Martínez-López E, Abad A, Font A et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998;114:1180-1187.
49. Popat S, Zhao D, Chen Z et al. Relationship between chromosome 18q status and colorectal cancer prognosis: A prospective, blinded analysis of 280 patients. Anticancer Res 2007;27:627-633.
50. Watanabe T, Wu TT, Catalano PJ et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-1206.
51. Bertagnolli MM, Niedzwiecki D, Hall M et al. Presence of 18q loss of heterozygosity (LOH) and disease-free and overall survival in stage II colon cancer: CALGB Protocol 9581 [abstract 4012]. J Clin Oncol 2009;27(15 suppl):171s.
52. Benson AB 3rd. New approaches to assessing and treating early-stage colon and rectal cancers: Cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 2007;13:6913s-6920s.
53. Tanaka T, Watanabe T, Kazama Y et al. Chromosome 18q deletion and Smad4 protein inactivation correlate with liver metastasis: A study matched for T- and N- classification. Br J Cancer 2006;95:1562-1567.
54. Alazzouzi H, Alhopuro P, Salovaara R et al. SMAD4 as a prognostic marker in colorectal cancer. Clin Cancer Res 2005;11:2606-2611.
55. Alhopuro P, Alazzouzi H, Sammalkorpi H et al. SMAD4 levels and response to 5-fluorouracil in colorectal cancer. Clin Cancer Res 2005;11:6311-6316.
56. Isaksson-Mettävainio M, Palmqvist R, Forssell J et al. SMAD4/DPC4 expression and prognosis in human colorectal cancer. Anticancer Res 2006;26:507-510.
57. Gaasenbeek M, Howarth K, Rowan AJ et al. Combined array-comparative genomic hybridization and single-nucleotide polymorphism-loss of heterozygosity analysis reveals complex changes and multiple forms of chromosomal instability in colorectal cancers. Cancer Res 2006;66:3471-3479.
58. Trautmann K, Terdiman JP, French AJ et al. Chromosomal instability in microsatellite-unstable and stable colon cancer. Clin Cancer Res 2006;12:6379-6385.
59. Walther A, Houlston R, Tomlinson I. Association between chromosomal instability and prognosis in colorectal cancer: A meta-analysis. Gut 2008;57:941-950.
60. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-310.
61. Elsaleh H, Powell B, McCaul K et al. P53 alteration and microsatellite instability have predictive value for survival benefit from chemotherapy in stage III colorectal carcinoma. Clin Cancer Res 2001;7:1343-1349.
62. Westra JL, Schaapveld M, Hollema H et al. Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients. J Clin Oncol 2005;23:5635-5643.
63. Petersen S, Thames HD, Nieder C et al. The results of colorectal cancer treatment by p53 status: Treatment-specific overview. Dis Colon Rectum 2001;44:322-333; discussion 333-334.
64. Munro AJ, Lain S, Lane DP. P53 abnormalities and outcomes in colorectal cancer: A systematic review. Br J Cancer 2005;92:434-444.
65. Lenz HJ, Danenberg KD, Leichman CG et al. p53 and thymidylate synthase expression in untreated stage II colon cancer: Associations with recurrence, survival, and site. Clin Cancer Res 1998;4:1227-1234.
66. Allegra CJ, Paik S, Colangelo LH et al. Prognostic value of thymidylate synthase, Ki-67, and p53 in patients with Dukes' B and C colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2003;21:241-250.
67. Russo A, Bazan V, Iacopetta B et al. The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: Influence of tumor site, type of mutation, and adjuvant treatment. J Clin Oncol 2005;23:7518-7528.
68. Popat S, Chen Z, Zhao D et al. A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer. Ann Oncol 2006;17:1810-1817.
69. Ahnen DJ, Feigl P, Quan G et al. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group study. Cancer Res 1998;58:1149-1158.
70. Elsaleh H, Powell B, Soontrapornchai P et al. p53 gene mutation, microsatellite instability and adjuvant chemotherapy: Impact on survival of 388 patients with Dukes' C colon carcinoma. Oncology 2000;58:52-59.
71. Lavin MF, Gueven N. The complexity of p53 stabilization and activation. Cell Death Differ 2006;13:941-950.
72. Goh HS, Yao J, Smith DR. p53 point mutation and survival in colorectal cancer patients. Cancer Res 1995;55:5217-5221.
73. Worthley DL, Whitehall VL, Spring KJ et al. Colorectal carcinogenesis: Road maps to cancer. World J Gastroenterol 2007;13:3784-3791.
74. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: The multicenter RASCAL study. J Natl Cancer Inst 1998;90:675-684.
75. Andreyev HJ, Norman AR, Cunningham D et al. Kirsten ras mutations in patients with colorectal cancer: The 'RASCAL II' study. Br J Cancer 2001;85:692-696.
76. Belly RT, Rosenblatt JD, Steinmann M et al. Detection of mutated K12-ras in histologically negative lymph nodes as an indicator of poor prognosis in stage II colorectal cancer. Clin Colorectal Cancer 2001;1:110-116.
77. Roth AD, Tejpar S, Delorenzi M et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: Results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 2010;28:466-474.
78. Ogino S, Meyerhardt JA, Irahara N et al. KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803. Clin Cancer Res 2009;15:7322-7329.
79. Karapetis CS, Khambata-Ford S, Jonker DJ et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-1765.
80. Bouzourene H, Gervaz P, Cerottini JP et al. p53 and Ki-ras as prognostic factors for Dukes' stage B colorectal cancer. Eur J Cancer 2000;36:1008-1015.
81. Zauber NP, Wang C, Lee PS et al. Ki-ras gene mutations, LOH of the APC and DCC genes, and microsatellite instability in primary colorectal carcinoma are not associated with micrometastases in pericolonic lymph nodes or with patients' survival. J Clin Pathol 2004;57:938-942.
82. Tortola S, Marcuello E, González I et al. p53 and K-ras gene mutations correlate with tumor aggressiveness but are not of routine prognostic value in colorectal cancer. J Clin Oncol 1999;17:1375-1381.
83. Esteller M, González S, Risques RA et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001;19:299-304.
84. Fuchs C, Ogino S, Meyerhardt JA et al. KRAS mutation, cancer recurrence, and patient survival in stage III colon cancer: Findings from CALGB 89803 [abstract 4037]. J Clin Oncol 2009;27(15 suppl):177s.
85. Lièvre A, Bachet JB, Boige V et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379.
86. Khambata-Ford S, Garrett CR, Meropol NJ et al. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007;25:3230-3237.
87. De Roock W, Piessevaux H, De Schutter J et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-515.
88. Van Cutsem E, Köhne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-1417.
89. Bokemeyer C, Bondarenko I, Makhson A et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009;27:663-671.
90. Amado RG, Wolf M, Peeters M et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634.
91. Rajagopalan H, Bardelli A, Lengauer C et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002;418:934.
92. Davies H, Bignell GR, Cox C et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-954.
93. Ikenoue T, Hikiba Y, Kanai F et al. Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors. Cancer Res 2003;63:8132-8137.
94. Fransén K, Klintenäs M, Osterström A et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 2004;25:527-533.
95. Samowitz WS, Sweeney C, Herrick J et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 2005;65:6063-6069.
96. Tol J, Nagtegaal ID, Punt CJ. BRAF mutation in metastatic colorectal cancer. N Engl J Med 2009;361:98-99.
97. Ogino S, Nosho K, Kirkner GJ et al. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009;58:90-96.
98. Pinedo HM, Peters GF. Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988;6:1653-1664.
99. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 1974;13:471-481.
100. Berger SH, Jenh CH, Johnson LF et al. Thymidylate synthase overproduction and gene amplification in fluorodeoxyuridine-resistant human cells. Mol Pharmacol 1985;28:461-467.
101. Edler D, Glimelius B, Hallström M et al. Thymidylate synthase expression in colorectal cancer: A prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J Clin Oncol 2002;20:1721-1728.
102. Johnston PG, Fisher ER, Rockette HE et al. The role of thymidylate synthase expression in prognosis and outcome of adjuvant chemotherapy in patients with rectal cancer. J Clin Oncol 1994;12:2640-2647.
103. Popat S, Matakidou A, Houlston RS. Thymidylate synthase expression and prognosis in colorectal cancer: A systematic review and meta-analysis. J Clin Oncol 2004;22:529-536.
104. Sakamoto J, Hamashima H, Suzuki H et al. Thymidylate synthase expression as a predictor of the prognosis of curatively resected colon carcinoma in patients registered in an adjuvant immunochemotherapy clinical trial. Oncol Rep 2003;10:1081-1090.
105. Soong R, Shah N, Salto-Tellez M et al. Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy. Ann Oncol 2008;19:915-919.
106. Kornmann M, Schwabe W, Sander S et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: Predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin Cancer Res 2003;9:4116-4124.
107. Sinicrope FA, Rego RL, Halling KC et al. Thymidylate synthase expression in colon carcinomas with microsatellite instability. Clin Cancer Res 2006;12:2738-2744.
108. Westra JL, Hollema H, Schaapveld M et al. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients. Ann Oncol 2005;16:1646-1653.
109. Salonga D, Danenberg KD, Johnson M et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-1327.
110. Leichman CG, Lenz HJ, Leichman L et al. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. J Clin Oncol 1997;15:3223-3229.
111. Morganti M, Ciantelli M, Giglioni B et al. Relationships between promoter polymorphisms in the thymidylate synthase gene and mRNA levels in colorectal cancers. Eur J Cancer 2005;41:2176-2183.
112. Mandola MV, Stoehlmacher J, Zhang W et al. A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 2004;14:319-327.
113. Lurje G, Zhang W, Yang D et al. Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics 2008;18:161-168.
114. Iacopetta B, Grieu F, Joseph D et al. A polymorphism in the enhancer region of the thymidylate synthase promoter influences the survival of colorectal cancer patients treated with 5-fluorouracil. Br J Cancer 2001;85:827-830.
115. Hitre E, Budai B, Adleff V et al. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil. Pharmacogenet Genomics 2005;15:723-730.
116. Roth AD, Tejpar S, Yan P et al. Tissue biomarkers (BIOM) in colon cancer (COC): The translational study on the randomized phase III trial comparing infused irinotecan/5-fluorouracil (5-FU)/folinic acid (FA) to 5-FU/FA in stage II-III COC patients (pts) [abstract 4022]. J Clin Oncol 2007;25:169s; updated information presented at the meeting.
117. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
118. Hayes DF, Bast RC, Desch CE et al. Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-1466.
119. McShane LM, Altman DG, Sauerbrei W et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst 2005;97:1180-1184.
120. Deutsch EW, Ball CA, Berman JJ et al. Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol 2008;26:305-312.
121. Nakao K, Mehta KR, Fridlyand J et al. High-resolution analysis of DNA copy number alterations in colorectal cancer by array-based comparative genomic hybridization. Carcinogenesis 2004;25:1345-1357.
122. Lips EH, van Eijk R, de Graaf EJ et al. Progression and tumor heterogeneity analysis in early rectal cancer. Clin Cancer Res 2008;14:772-781.
123. Oosting J, Lips EH, van Eijk R et al. High-resolution copy number analysis of paraffin-embedded archival tissue using SNP BeadArrays. Genome Res 2007;17:368-376.
124. Thomas RK, Baker AC, Debiasi RM et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 2007;39:347-351.
125. Farragher SM, Tanney A, Kennedy RD et al. RNA expression analysis from formalin fixed paraffin embedded tissues. Histochem Cell Biol 2008;130:435-445.
126. Devries S, Nyante S, Korkola J et al. Array-based comparative genomic hybridization from formalin-fixed, paraffin-embedded breast tumors. J Mol Diagn 2005;7:65-71.
127. Hoshida Y, Villanueva A, Kobayashi M et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008;359:1995-2004.
128. Clark-Langone KM, Wu JY, Sangli C et al. Biomarker discovery for colon cancer using a 761 gene RT-PCR assay. BMC Genomics 2007;8:279.
129. Braun MS, Richman SD, Quirke P et al. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: Results from the UK MRC FOCUS trial. J Clin Oncol 2008;26:2690-2698.
130. Yu J, Shannon WD, Watson MA et al. Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res 2005;11:2053-2062.
131. Swanton C, Marani M, Pardo O et al. Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs. Cancer Cell 2007;11:498-512.
132. Swanton C, Nicke B, Marani M et al. Initiation of high frequency multi-drug resistance following kinase targeting by siRNAs. Cell Cycle 2007;6:2001-2004.
133. Swanton C, Tomlinson I, Downward J. Chromosomal instability, colorectal cancer and taxane resistance. Cell Cycle 2006;5:818-823.
134. Bild AH, Yao G, Chang JT et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006;439:353-357.
135. Potti A, Dressman HK, Bild A et al. Genomic signatures to guide the use of chemotherapeutics. Nat Med 2006;12:1294-1300.
136. Dressman HK, Berchuck A, Chan G et al. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol 2007;25:517-525.
137. Salter KH, Acharya CR, Walters KS et al. An integrated approach to the prediction of chemotherapeutic response in patients with breast cancer. PLoS ONE 2008;3:e1908.
138. Perou CM, Sørlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000;406:747-752.
139. Sørlie T, Perou CM, Tibshirani R et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:10869-10874.
140. van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
141. Buyse M, Loi S, van't Veer L et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-1192.
142. Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J Clin Oncol 2006;24:1665-1671.
143. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-2826.
144. Ma X, Hilsenbeck S, Wang W et al. The HOXB13:IL17BR expression index is a prognostic factor in early-stage breast cancer. J Clin Oncol 2006;24:4611-4619.
145. Chang HY, Nuyten DS, Sneddon JB et al. Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. Proc Natl Acad Sci U S A 2005;102:3738-3743.
146. Fan C, Oh DS, Wessels L et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560-569.
147. Wirapati P, Sotiriou C, Kunkel S et al. Meta-analysis of gene expression profiles in breast cancer: Toward a unified understanding of breast cancer subtyping and prognosis signatures. Breast Cancer Res 2008;10:R65.
148. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: Understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006;98:262-272.
149. Wang Y, Jatkoe T, Zhang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004;22:1564-1571.
150. Barrier A, Boelle PY, Roser F et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006;24:4685-4691.
151. Michiels S, Koscielny S, Hill C. Interpretation of microarray data in cancer. Br J Cancer 2007;96:1155-1158.
152. Kim GP, Colangelo LH, Wieand HS et al. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: A National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project collaborative study. J Clin Oncol 2007;25:767-772.
153. Deschoolmeester V, Van Damme N, Baay M et al. Microsatellite instability in sporadic colon carcinomas has no independent prognostic value in a Belgian study population. Eur J Cancer 2008;44:2288-2295.
154. Lanza G, Matteuzzi M, Gafa R et al. Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998;79:390-395.